National and Kapodistrian University of Athens
Ο ιός Epstein-Barr (EBV) και η μεμβρανική πρωτεΐνη 1 της λανθάνουσας φάσης (LMP-1) στη χρόνια λεμφογενή λευχαιμία και τα λεμφώματα χαμηλής κακοήθειας
Abstract
dc:descriptionEpstein-Barr virus (EBV) is a universally present herpesvirus that can cause a latent infection of the memory Β cells. During latency, it expresses only a small part of its genome, comprising of six nuclear antigens (EBNAs), two EBV encoded RNAs (EBER1/2) and two latent membrane proteins (LMP1/2).LMP1 is a strong imitator of CD40 and is implicated in the malignant transformation of EBV infected cells, through antiapoptotic signals and NF-kB activation. Recently, it has been shown that its role may be more complex, with antiapoptotic as well as apoptotic properties.Our aim was to investigate the role of EBV and LMP1 in non-EBV related entities, such as chronic lymphocytic leukemia (CLL) and low grade B-cell lymphoma,Patients with CLL and low grade B-cell lymphoma with immunophenotypically confirmed disease by blood were enrolled. DNA, RNA and protein extraction were carried out before and after 3 cycles of rituximab-based immunochemotherapy. The EBV viral load was quantified by real time PCR, LMP1-mRNA was detected by RT-PCR and LMP1-protein by ELISA. FcgRIIA polymorphisms were detected by allele specific restriction enzyme digestion (ASRED). Survivin-mRNA was quantified by real time RT-PCR.Sixty five patients were enrolled. The results are as follows.A.Correlation of FcgRIIA polymorphisms with EBV and LMP1. We detected FcgRIIApolymorphisms in the blood samples of 40 patients and showed that the R131 polymorphic locus waspresent in 84.2% of EBV+, but only in 28.5% of EBV- patients (p=0.001). The correlation with LMP1expression was quite similar (84.5% vs 28.5%, p=0.002) and shows that FcgRIIA polymorphismsconstitute a genetic risk factor for EBV latency and LMP1 expression.B.Correlation of survivin levels with EBV and LMP1. Survivin is a member of the inhibitors ofapoptosis (LAP) family, and is implicated in the pathogenesis of neoplasia. Survivin-mRNA levels weremeasured in 64 patients and found 8.37 times higher in EBV- patients (p=0.002) and 6.36 times higherin LMP1- patients (p=0.008), a result implying a preponderance of LMP1 apoptotic effects in thispatient group.C.Investigation of the effect of rituximab on the EBV load of 44 patients that were treated withrituximab based immunochemotherapy. Among 17 EBV+ patients, only one had a persistentlymeasurable viral load following treatment. Moreover, this was the only patient with disease progressiondespite treatment. Rituximab is able to eradicate EBV from the blood, although it is responsible forreactivation of other viral infections. This fact may have several interesting implications that remain tobe studied.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Diamantopoulos, Panagiotis
- Διαμαντόπουλος, Παναγιώτης
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/37887